Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPTNASDAQ:ARQTNASDAQ:DYNNASDAQ:RAPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$10.47+3.3%$8.92$2.99▼$10.87$1.54B1.81.57 million shs2.89 million shsARQTArcutis Biotherapeutics$13.67+3.1%$13.85$7.86▼$17.75$1.58B1.762.25 million shs2.33 million shsDYNDyne Therapeutics$10.78-0.7%$11.46$6.36▼$47.45$1.23B1.161.74 million shs3.01 million shsRAPPRapport Therapeutics$11.03+0.7%$10.68$6.43▼$29.74$399.65MN/A167,943 shs132,616 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-1.46%-3.06%+12.04%+34.13%+222.93%ARQTArcutis Biotherapeutics-1.04%-4.54%-6.02%-20.12%+66.58%DYNDyne Therapeutics-21.42%-26.52%-8.20%-12.42%-65.84%RAPPRapport Therapeutics-2.23%-16.79%+9.94%+11.96%+1,094,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADPTAdaptive Biotechnologies2.8277 of 5 stars1.41.00.04.22.92.50.6ARQTArcutis Biotherapeutics2.3203 of 5 stars3.41.00.00.03.31.70.6DYNDyne Therapeutics2.4431 of 5 stars4.50.00.00.01.92.50.0RAPPRapport Therapeutics1.9899 of 5 stars3.50.00.00.03.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.86Moderate Buy$10.570.97% UpsideARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8037.53% UpsideDYNDyne Therapeutics 3.00Buy$43.93307.50% UpsideRAPPRapport Therapeutics 3.00Buy$32.67196.16% UpsideCurrent Analyst Ratings BreakdownLatest RAPP, ARQT, DYN, and ADPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025ADPTAdaptive BiotechnologiesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.006/18/2025DYNDyne TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/18/2025DYNDyne TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$46.00 ➝ $32.006/17/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/11/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$37.006/2/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$60.00 ➝ $34.005/29/2025DYNDyne TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.005/23/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/9/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$46.00 ➝ $38.005/9/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.005/6/2025ADPTAdaptive BiotechnologiesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$11.00 ➝ $13.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$178.96M8.89N/AN/A$1.37 per share7.64ARQTArcutis Biotherapeutics$196.54M8.29N/AN/A$1.35 per share10.13DYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/ARAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.96N/AN/AN/A-74.84%-62.79%-24.55%7/30/2025 (Estimated)ARQTArcutis Biotherapeutics-$140.04M-$1.04N/AN/AN/A-60.95%-80.66%-32.94%8/13/2025 (Estimated)DYNDyne Therapeutics-$317.42M-$3.59N/AN/AN/AN/A-52.83%-48.84%8/11/2025 (Estimated)RAPPRapport Therapeutics-$78.31M-$3.45N/AN/AN/AN/A-25.48%-24.63%8/14/2025 (Estimated)Latest RAPP, ARQT, DYN, and ADPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/8/2025Q1 2025RAPPRapport Therapeutics-$0.77-$0.68+$0.09-$0.68N/AN/A5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million5/1/2025Q1 2025ADPTAdaptive Biotechnologies-$0.28-$0.20+$0.08-$0.20$42.13 million$52.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.922.82ARQTArcutis Biotherapeutics0.753.553.37DYNDyne TherapeuticsN/A20.3520.35RAPPRapport TherapeuticsN/A31.0131.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%ARQTArcutis BiotherapeuticsN/ADYNDyne Therapeutics96.68%RAPPRapport TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%ARQTArcutis Biotherapeutics9.40%DYNDyne Therapeutics14.14%RAPPRapport TherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790151.92 million142.19 millionOptionableARQTArcutis Biotherapeutics150119.20 million108.00 millionOptionableDYNDyne Therapeutics100113.67 million97.59 millionOptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/ARAPP, ARQT, DYN, and ADPT HeadlinesRecent News About These CompaniesAnalysts Can't Get Enough of These Little-Known Biopharma Stocks (RAPP)June 12, 2025 | marketbeat.comStifel reiterates buy rating for Rapport Therapeutics stockJune 5, 2025 | uk.investing.comRapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical PipelineJune 4, 2025 | nasdaq.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Up 16% - Still a Buy?June 4, 2025 | marketbeat.comRapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate UpdatesJune 2, 2025 | globenewswire.comRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare ConferenceMay 27, 2025 | globenewswire.comRapport Therapeutics (RAPP) to Release Quarterly Earnings on MondayMay 27, 2025 | marketbeat.comRapport Therapeutics to Host 2025 Investor and Analyst DayMay 21, 2025 | globenewswire.comCompanies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In GrowthMay 17, 2025 | finance.yahoo.comRapport Therapeutics Reports Q1 2025 Financial ResultsMay 10, 2025 | tipranks.comOptimistic Buy Rating for Rapport Therapeutics Driven by Promising RAP-219 DevelopmentsMay 8, 2025 | tipranks.comPromising Clinical Developments and Strategic Initiatives Drive Buy Rating for Rapport Therapeutics, Inc.May 8, 2025 | tipranks.comRapport Therapeutics Reports First Quarter 2025 Financials and Provides Business UpdateMay 8, 2025 | globenewswire.comInductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI PlatformMay 7, 2025 | finance.yahoo.comWhy Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 5.49%May 3, 2025 | aaii.comMise à disposition du rapport financier annuel 2024April 30, 2025 | globenewswire.comWhy Rapport Therapeutics, Inc.’s (RAPP) Stock Is Up 7.06%April 29, 2025 | aaii.comRapport Therapeutics to Participate in Upcoming Investor ConferencesApril 22, 2025 | globenewswire.comMeloni and Trump: An Oval Office Meeting With Rapport and BanterApril 18, 2025 | nytimes.comRapport Therapeutics initiated with an Outperform at Citizens JMPApril 9, 2025 | markets.businessinsider.comBuy Rating for Rapport Therapeutics: Promising Precision Therapeutics for CNS DisordersApril 9, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueAfter Earnings Beats, These 3 Stocks Are on Analysts’ RadarsBy Leo Miller | May 20, 2025View After Earnings Beats, These 3 Stocks Are on Analysts’ RadarsJoby's Saudi MoU: Strong Initial Reaction Meets Market DynamicsBy Jeffrey Neal Johnson | June 4, 2025View Joby's Saudi MoU: Strong Initial Reaction Meets Market DynamicsSteel Dynamics Shares Climb After Tariff AnnouncementBy Dan Schmidt | June 3, 2025View Steel Dynamics Shares Climb After Tariff AnnouncementRAPP, ARQT, DYN, and ADPT Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$10.47 +0.33 (+3.25%) Closing price 04:00 PM EasternExtended Trading$10.44 -0.03 (-0.29%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Arcutis Biotherapeutics NASDAQ:ARQT$13.67 +0.41 (+3.09%) Closing price 04:00 PM EasternExtended Trading$13.66 -0.02 (-0.11%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Dyne Therapeutics NASDAQ:DYN$10.78 -0.08 (-0.74%) Closing price 04:00 PM EasternExtended Trading$10.72 -0.05 (-0.51%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Rapport Therapeutics NASDAQ:RAPP$11.03 +0.08 (+0.73%) Closing price 04:00 PM EasternExtended Trading$11.04 +0.02 (+0.14%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
